Telomeres in cancer and ageing by Donate, Luis E. & Blasco, Maria A.
Review
Telomeres in cancer and ageing
Luis E. Donate and Maria A. Blasco*
Telomeres and Telomerase Group, Molecular Oncology Programme, Spanish National Cancer Research
Centre (CNIO), Melchor Ferna ´ndez Almagro, 3, 28029 Madrid, Spain
Telomeres protect the chromosome ends from unscheduled DNA repair and degradation.
Telomeres are heterochromatic domains composed of repetitive DNA (TTAGGG repeats) bound
to an array of specialized proteins. The length of telomere repeats and the integrity of telomere-
binding proteins are both important for telomere protection. Furthermore, telomere length and
integrity are regulated by a number of epigenetic modiﬁcations, thus pointing to higher order con-
trol of telomere function. In this regard, we have recently discovered that telomeres are transcribed
generating long, non-coding RNAs, which remain associated with the telomeric chromatin and are
likely to have important roles in telomere regulation. In the past, we showed that telomere length
and the catalytic component of telomerase, Tert, are critical determinants for the mobilization of
stem cells. These effects of telomerase and telomere length on stem cell behaviour anticipate the
premature ageing and cancer phenotypes of telomerase mutant mice. Recently, we have demon-
strated the anti-ageing activity of telomerase by forcing telomerase expression in mice with
augmented cancer resistance. Shelterin is the major protein complex bound to mammalian telo-
meres; however, its potential relevance for cancer and ageing remained unaddressed to date. To
this end, we have generated mice conditionally deleted for the shelterin proteins TRF1, TPP1
and Rap1. The study of these mice demonstrates that telomere dysfunction, even if telomeres are
of a normal length, is sufﬁcient to produce premature tissue degeneration, acquisition of chromo-
somal aberrations and initiation of neoplastic lesions. These new mouse models, together with
the telomerase-deﬁcient mouse model, are valuable tools for understanding human pathologies
produced by telomere dysfunction.
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1. ROLE OF TELOMERASE IN ADULT
STEM CELLS
(a) Telomeres
Telomeres are ribonucleoprotein complexes at the
ends of chromosomes that are essential for chromo-
some protection and genomic stability. Telomeres
consist of tandem repeats of a DNA sequence rich in
G bases (TTAGGG in all vertebrates) bound by a
six-protein complex known as shelterin. Shelterin
encompasses the Pot1-TPP1 heterodimer, the telo-
mere-binding proteins TRF1 and TRF2, and the
interacting factors Rap1 and Tin2 [1].
Telomeric chromatin is also enriched in epigenetic
marks that are characteristic of constitutive hetero-
chromatin, such as histone tri-methylation and DNA
hypermethylation, which act as negative regulators of
telomere length and telomere recombination [2].
Telomere shortening below a certain threshold
length and/or alterations in the functionality of the
telomere-binding proteins can result in loss of telo-
meric protection, leading to end-to-end chromosome
fusions, cell cycle arrest and/or apoptosis. Telomeres
also perform other functions, which include the tran-
scriptional silencing of genes located close to the
telomeres (this phenomenon is termed subtelomeric
silencing), as well as ensuring correct chromosome
segregation during mitosis.
(b) Telomerase
Shortening of telomeres is associated with each round of
cell division owing to the inability of conventional DNA
polymerasestoreplicatetheendsoflinearchromosomes,
the so-called ‘end replication problem’. Telomerase is a
cellularenzyme capableofcompensatingthis progressive
telomereattritionthroughdenovoadditionofTTAGGG
repeatstothe chromosome ends [3].Telomeraseencom-
passes a catalytic subunit with reverse transcriptase
activity (Tert), an RNA component (Terc) that acts as a
template for DNA synthesis and the protein dyskerin
(Dkc1), which binds and stabilizes Terc.
Robust telomerase expression is a feature of pluri-
potent stem cells and early stages of embryonic
development, although telomerase activity is also pres-
ent in adult stem cell compartments [4]. Telomerase
activity in adult tissues, however, is not sufﬁcient to
prevent telomere shortening associated with ageing.
Mutations in the different components of telomer-
ase (Tert, Terc and Dkc1), as well as in some
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Figure 1. Progressive decrease in median and maximum life-
spans along successive generations of telomerase-null mice.
Cohorts of successive generations of telomerase-deﬁcient
mice (wild-type, black dashed line; ﬁrst generation G1
Terc
2/2, blue dashed line; second generation G2 Terc
2/2,
green dashed line; third generation G3 Terc
2/2,r e d
dashed line) were followed up for a period of 32 months.
The ﬁgure shows a Kaplan–Meier representation of the sur-
vival of the following groups of mice: Terc
þ/þ, n ¼ 68; G1
Terc
2/2, n ¼ 17; G2 Terc
2/2, n ¼ 31; G3 Terc
2/2, n ¼ 22.
Telomerase-deﬁcient mice have a shorter lifespan than the
telomerase-proﬁcient mice, which is further shortened with
increasing mouse generations.
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Figure 2. A stem cell-based model for the role of telomeres in cancer and ageing. The longest telomeres mark the stem cell
compartments (niches). In young or adult organisms, stem cells (blue rounded cells) repopulate tissues as needed: they exit
from the niche, proliferate and differentiate (square orange cells). During this process, stem cells undergo telomere shortening,
which is partially counterbalanced by the action of telomerase. In old organisms, stem cell telomeres are too short. Critically
short telomeres are recognized as DNA damage, activating a p53-mediated DNA damage signalling response that impairs stem
cell mobilization and, as a consequence, the tissue regeneration is suboptimal leading ultimately to organ failure. A decreased
stem cell mobilization reduces the probability of accumulating abnormal cells in tissues, providing a mechanism for cancer
protection. If the stem cells express aberrantly high levels of telomerase (by acquisition of tumorigenic, telomerase-reactivating
mutations), stem cell mobilization is more efﬁcient than normal. Under these higher mobilization conditions, tissue ﬁtness
would be maintained for a longer time, increasing lifespan and also the probabilities of initiating a tumour.
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etic diseases, such as dyskeratosis congenita, aplastic
anaemia and idiopathic pulmonary ﬁbrosis [5–8].
These diseases are associated with the presence of
short/dysfunctional telomeres and they all exhibit a
characteristic failure in the regenerative capacity of tis-
sues (such as the bone marrow) and severe skin
hyperpigmentation.
2. THE TELOMERASE-DEFICIENT MOUSE MODEL
Generation of telomerase-deﬁcient mice (Terc
knock-out mice) allowed the ﬁrst demonstration
that telomerase is required for telomere maintenance
in the context of mammalian organisms, as well as
its importance for cancer and ageing. Thus, telomer-
ase-deﬁcient cells exhibit an accelerated telomere
shortening that eventually leads to loss of telomere
protection and end-to-end chromosome fusions
[9–12]. Complete survival curves of increasing gen-
erations of telomerase-null mice (G1–G3) [13]
indicated that telomere shortening along successive
mouse generations [12,14–15] was paralleled by a
progressive decrease in both median and maximum
longevity (ﬁgure 1). Telomerase and telomere main-
tenance are considered, therefore, to be rate limiting
for mouse longevity.
Additionally, telomerase-deﬁcient mice developed
premature ageing pathologies with an onset that is
anticipated with increasing mouse generations (simi-
larly to the human diseases linked to telomere
dysfunction), in agreement with inheritance of shorter
telomeres after each generation. Finally, telomerase-
deﬁcient mice show increased resistance to cancer,
validating telomerase as a promising target for
anti-tumour therapies [16].
(a) Telomerase in adult stem cells
As telomerase expression is restricted to stem cell com-
partments in the context of the adult organism, it is of
interest to determine the impact of telomere shorten-
ing on stem cell ageing. Stem cell functionality,
measured as the ability of epidermal stem cells to
mobilize and regenerate the skin and the hair, is dra-
matically impaired in telomerase-deﬁcient mice with
critically short telomeres (as is the case of G3 telo-
merase-null mice), a defect that is rescued by either
telomerase re-introduction and elongation of short
telomeres, or by p53 suppression [17,18]. In this
regard, all stem cell defects associated with the presence
of critically short telomeres, such as the length of the
hair bulb and the thickness of the interfollicular epider-
mis, are fully rescued in mice doubly deﬁcient for
telomerase and p53 when compared with single tel-
omerase-deﬁcient mice. These results identify p53 as
an important checkpoint for stem cell and tissue
ﬁtness, in a manner that only those stem cells with suf-
ﬁciently long telomeres will be allowed to regenerate
tissues [19].
(b) Role of telomeres in cancer and ageing:
a stem cell-based model
We have proposed a stem cell-based model for the role
of telomeres in cancer and ageing, which is
summarized in ﬁgure 2. Adult stem cells reside at
speciﬁc compartments within tissues, the so-called
niches, which are enriched in cells with the longest
telomeres [20]. In young or adult organisms with
sufﬁcient telomere reserve, adult stem cells efﬁciently
repopulate tissues and repair lesions as needed. In
old organisms, however, stem cell telomeres may be
too short [20], and this could impair the mobilization
of stem cells and the ability to repair tissues efﬁciently.
When telomeres have shortened down to a critical
length they are recognized as DNA damage, activating
a p53-mediated DNA damage signalling response that
prevents the mobilization of the stem cells out of their
niches. Decreased stem cell mobilization reduces the
probability of accumulating abnormal cells in tissues,
thus providing a mechanism for cancer protection.
However, the ultimate consequence of impaired
mobilization of the stem cells will be organ failure
owing to tissue degeneration.
By using mouse models over-expressing telo-
merase, we and others showed that elevated TERT
expression increases stem cell mobilization. Under
these conditions of higher mobilization, the ﬁtness
of the tissues would be maintained for longer times,
therefore increasing the lifespan. The probabilities
of initiating a tumour, however, are also higher,
especially so if telomerase reactivation occurs in a
context of mutations in the tumour suppressors [21].
3. LONGEVITY EXTENSION BY TELOMERASE
As discussed in §2, the study of telomerase-deﬁcient
mice suggests that telomerase is rate limiting for
mouse longevity. We next wondered whether tel-
omerase over-expression can extend longevity and, if
so, to what extent. We previously observed that while
telomerase deﬁciency results in a lower incidence of
cancer [16], constitutive telomerase over-expression
results in a slightly increased incidence of cancer
(ﬁgure 3)[ 22]. To counterbalance this undesired
effect of telomerase over-expression, we over-
expressed telomerase in the context of cancer-resistant
mice having increased levels of the tumour suppressors
p53, p16 and p19ARF (SUPER-M mice; ﬁgure 3). In
these mice, the effects of telomerase on cancer and
ageing will be dissociated, therefore allowing assess-
ment of the role of telomerase on the ageing and
ﬁtness of mice.
(a) SUPER-M mice
Characterization of the SUPER-M mice showed a
cancer appearance that was signiﬁcantly delayed:
while in wild-type mice, cancer was detectable at
110 weeks of age (and earlier in those mice
over-expressing telomerase), in the SUPER-M
mice tumours did not appear until 145 weeks of
age [23].
The age for the onset of degenerative lesions is
also delayed in SUPER-M mice. In these mice, the
symptoms of ageing are also attenuated: for instance,
levels of subcutaneous fat are very similar in young
and older SUPER-M mice, while the thickness of
the subcutaneous fat layer in older wild-type mice
is seven times less than that of young wild-type
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ageing of the skin; the skin and hair coat of elderly
SUPER-M mice are better than of elderly
wild-type mice.
Organism ageing of SUPER-M mice is also less:
thus neuromuscular ﬁtness is improved in old
mice. All the SUPER-M mice successfully passed
the neuromuscular coordination test, while not all
the wild-type mice were successful in this test, and
over half the aged mice failed. SUPER-M mice
also had improved glucose tolerance, three times
better than that of wild-type mice. SUPER-M mice
have longer telomeres than wild-type mice, and this
difference in telomere length is much greater in
elderly mice. Also, aged SUPER-M mice showed
less damage in their telomeric DNA than the aged
wild-type mice.
Given the above-described anti-ageing activity of
telomerase in the SUPER-M mice, we addressed
whether the tranagenic Tert (TgTert) allele had an
effect on the lifespan of the cancer-resistant Sp53
and Sp53/Sp16/SArf mice. We obtained survival
curves covering the entire lifespan of the Sp53/
TgTert and the Sp53/Sp16/SArf/TgTert mice
(SUPER-M), compared with Sp53 and Sp53/Sp16/
SArf controls; all these mice have the same genetic
background composition. We used Sp53 mice as a
reference for normal longevity in our mouse cohorts
because they have been previously shown to have the
same longevity as wild-type mice in two independent
studies [24,25]. Analysis of the survival curves indi-
cated a signiﬁcant extension of median lifespan of 9
per cent and 26 per cent by TgTert expression in
the context of cancer-resistant Sp53 and Sp53/Sp16/
SArf mice, respectively (ﬁgure 4a). To further dis-
sociate the effects of TgTert expression on cancer
and ageing, we considered separately the lifespan of
the cancer-free mice (i.e. those mice that died without
malignant tumours; ﬁgure 4b). The lifespans of this
subgroup are determined by ageing and not by
cancer, and we observed an even more evident
impact of TgTert expression, resulting in a median
lifespan extension of 18 per cent and 38 per cent in
the Sp53/TgTert and Sp53/Sp16/SArf/TgTert
(SUPER-M) mice, respectively, compared with the
Sp53 and Sp53/Sp16/SArf controls (ﬁgure 4b). Fur-
thermore, combined TgTert and Sp53/Sp16/SArf
transgenes resulted in a 40.2 per cent extension of
the median lifespan when compared with single
Sp53 mice (our reference for normal longevity),
which was further increased to 50 per cent when con-
sidering cancer-free mice (ﬁgure 4b). We also studied
the group of longest lived mice of each genotype to
estimate whether TgTert expression had an effect on
maximum longevity. The percentage of mice that
reached the extremely old age of 3 years was signiﬁ-
cantly larger for the SUPER-M mice than for their
Sp53/Sp16/SArf controls (42% versus 8%), and this
extreme survival is further increased when considering
cancer-free mice (up to 50%). The mean age of the
upper longevity quartile was signiﬁcantly higher in
SUPER-M mice than in their Sp53/Sp16/SArf con-
trols (163 weeks versus 146 weeks). These
observations indicate that TgTert expression changes
the longevity curve of mice, signiﬁcantly extending
the median lifespan and signiﬁcantly increasing the
percentage of mice that reach extremely old ages. We
also wondered whether the observed effects of
telomerase on longevity involve its telomere-mainten-
ance activity. To this end, we examined the longevity
curve of TgTert mice lacking the RNA component
of telomerase (Terc), which is essential for telomerase
catalytic activity. We observed that TgTert does not
have an effect on the longevity curve of Terc-deﬁcient
mice across different generations up to the fourth
generation (G2–G4). These results indicate that the
anti-ageing activity of Tert requires telomerase catalytic
activity, which strongly implicates telomere mainten-
ance as the main mechanism underlying the
longevity enhancing effect of telomerase expression.
4. TELOMERE REJUVENATION DURING THE
GENERATION OF INDUCED PLURIPOTENT
STEM CELLS
To obtain induced pluripotent stem (iPS) cells from
adult differentiated cells is a key goal in the development
of customized cellular therapies. This type of cell would
represent an unlimited source of cells capable of generat-
ing all kind of tissues, with the added advantage of
avoiding rejection in cell transplantation therapies, as
they originate from the same individual. The ﬁrst
approach to nuclear reprogramming was based on
nuclear transplantation from somatic cells to enucleated
oocytes [26]. Recently, iPS cells have been generated
from differentiated cells by the introduction of four tran-
scription factors, Oct4, Sox2, Klf4 and c-Myc [27–28].
However, c-Myc is dispensable in the generation of
iPS cells.
As previously stated, telomeres shorten with age,
thus contributing to organism ageing by limiting the
proliferative capacity of adult stem cells. Although it
was known that telomerase activity was augmented in
both human and murine iPS cells, it remained
unknown whether telomeres re-elongated during
nuclear reprogramming and whether the telomeric
chromatin would acquire the same characteristics as
those of embryonic stem cells (ﬁgure 5).
Reprogramming of telomeric chromatin can take
place in several possible scenarios: telomerase might
not be needed for telomere elongation, telomerase
might cooperate with recombination-based mechan-
isms or, ﬁnally, telomere elongation during nuclear
reprogramming might completely depend on telomer-
ase activity. We demonstrated that in iPS cells, the
telomeres greatly elongate with respect to the telo-
meres of the parental differentiated cells [29]. This
elongation occurs independently of the presence or
absence of c-Myc. Furthermore, the efﬁciency of
elongation of telomeres during the generation of iPS
cells was the same whether the starting cells were
derived from young or elderly individuals. These
results, therefore, indicate that telomeres efﬁciently
rejuvenate during nuclear reprogramming of differen-
tiated cells. The elongation of telomeres continues
post-reprogramming until they reach the length of
the telomeres of the embryonic stem cells. During
the reprogramming of telomerase-null cells the
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that telomere elongation during nuclear reprogram-
ming of differentiated cells is exclusively mediated by
telomerase activity [29].
We also demonstrated that the telomeres of iPS cells
acquire the epigenetic marks of the telomeres of
embryonic stem cells, among them a low density of tri-
methylated histones H3K9 and H4K20, and that in
the iPS cells there is a loss of telomeric silencing and
an increase in the abundance of TERRA (telomeric
transcripts) levels [29].
We observed that the reprogramming efﬁciency of
cells derived from increasing generations of telomer-
ase-deﬁcient mice is drastically reduced, and this
defect is annulled after telomerase reintroduction
[29]. We also observed that the generation of iPS
cells needs a minimum telomere length. In fact,
when we employed cells derived from the G3
generation of telomerase-deﬁcient mice, reprogram-
ming is impaired, indicating the existence of a
minimum required telomeric length for iPS cells to
be obtained [29].
5. p53 IS A KEY FACTOR LIMITING
REPROGRAMMING OF SUBOPTIMAL CELLS
The fact that cells with short telomeres are not subject
to nuclear reprogramming very probably indicates that
some ‘reprogramming barriers’ abort the reprogram-
ming of suboptimal parental cells bearing uncapped
or dysfunctional telomeres. To explain this observation,
we hypothesise low reprogramming rates resulting from
the presence of DNA damage in the starting cells. We
have demonstrated that the tumour suppressor p53 is
a key factor that limits the reprogramming of subopti-
mal cells, those bearing different kinds of DNA
damage such as short telomeres, having deﬁciencies in
their DNA repair systems (ATM- and 53BP1-deﬁcient
cells) or exogenously inﬂicted DNA damage (irradiated
cells) [30].
Reprogramming in the face of pre-existing but toler-
ated DNA damage is aborted by the activation of the
p53-dependent DNA damage response (DDR) and
apoptosis. p53 suppression allows an efﬁcient repro-
gramming of cells harbouring persistent DNA damage
and chromosomal aberrations. We have observed that
during reprogramming, the cells increase their intoler-
ance to the different types of DNA damage and that
p53 is critical in avoiding the generation of iPS cells
from suboptimal parental cells [30]. Finally, given that
certain reprogramming factors promote in vivo tumori-
genesis, it is tempting to propose that the DDR
observed in cultures of p53-deﬁcient cells might be
equivalent to the oncogene-induced DDR that takes
place during malignant transformation. For the two
scenarios nuclear reprogramming and malignant trans-
formation, p53 is critical in controlling the
dissemination of damaged cells.
Our results highlight the importance of telomere
biology in the generation and functionality of iPS
cells, and have important implications for the
clinical translation of iPS cell technologies,
particularly in patients afﬂicted with the so-called
‘telopathies’.
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Figure 3. Lifespan extension by telomerase. To address whether telomerase over-expression had an effect on mouse longevity,
we ﬁrst took into account that the absence of telomerase (the Terc knock-out mice) results in premature ageing and also in a
lesser incidence of cancer. Second, the constitutive over-expression of telomerase in the epithelia, while attenuating the ageing
phenotypes, also increased the incidence of cancer in the epithelia. We generated SUPER-M mice, a mouse model in which
the constitutive over-expression of telomerase takes place in a genetic background of increased resistance to cancer achieved by
means of over-expression of the tumour suppressors p53, p16 and p19ARF. In the SUPER-M mice, the effects of telomerase
on cancer and ageing will be dissociated.
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OF CANCELLING THE DNA DAMAGE RESPONSE
AT CHROMOSOME ENDS
(a) The shelterin complex
The TTAGGG repeats at the end of mammalian
chromosomes associate to a six-protein complex termed
shelterin. Shelterin enables cells to distinguish their
natural chromosome ends from breaks in the DNA
strand by cancelling a DDR at telomeres, as well as
regulating telomere length. Telomeres contain addition-
ally a number of proteins that are not part of the
shelterin complex, but also have non-telomere-related
functions.
The speciﬁcity of shelterin for telomeric DNA is
through direct recognition of the TTAGGG sequence
by three of its components. In particular, TRF1 and
TRF2 bind to the double stranded region of telomeric
DNA, while Pot1 binds to the TTAGGG repeats of
the G-overhang. TRF1 and TRF2 recruit the other
four components of shelterin: Tin2 (a TRF1 and
TRF2 interacting factor), Rap1, TPP1 and Pot1.
These last two proteins form a heterodimer. Shelterin
can form a stable complex in the absence of telomeric
DNA.
Some mutations in Tin2 as well as genetic variants
of TRF1 have been described linked to the rare human
diseases dyskeratosis congenita and aplastic anaemia.
These conditions [31–33] have as hallmarks epithelial
abnormalities, such as skin hyperpigmentation, nail
dystrophy and oral leukoplakia.
7. MOUSE MODELS FOR CONDITIONALLY
DELETED SHELTERIN PROTEINS
(a) TRF1
D/D mice
The conventional deletion of the shelterin protein
TRF1 in mice is lethal embryonically very early
during the blastocyst stage, and for this reason the
characterization of the role of TRF1 in differentiated
cells has remained impractical.
To study the role of TRF1 in telomere biology and
disease in the context of a mammalian organism we
generated cells and mice in which TRF1 was con-
ditionally deleted speciﬁcally in epithelial (TRF1
D/D
K5-Cre) mice [34]. TRF1 deletion in mouse
embryonic ﬁbroblasts (MEFs) did not result in
changes in telomere length; on the contrary, it led
to a rapid induction of p53/RB-dependent cellular
senescence concomitant with the accumulation of
abundant damage foci at telomeric DNA. This
persistent DNA damage activated phosphorylation
of the ATM/ATR kinases and their downstream
effectors, the kinases CHK1 and CHK2, resulting
in cell cycle arrest. Cells deﬁcient in TRF1 showed
abundant end-to-end telomere fusions involving
both chromosomes and sister chromatids. We also
observed abundant multi-telomeric signals, which
are indicative of a high degree of chromosomal fragi-
lity that arises from problems in the replication of
telomeric DNA [34,35]. Our results demonstrate
that TRF1 exerts a protective function against the
DDR at telomeres, and that it facilitates the
replication of telomeric DNA.
(b) Consequences of TRF1 deletion in
adult stem cells
In accordance with severe telomere dysfunction,
TRF1
D/DK5-Cre mice die perinatally and show
reduced skin thickness and reduced skin stratiﬁcation,
as well as severe skin hyperpigmentation. Newborn
mice also have focal dysplasia in the epithelia of the
palate, the non-glandular stomach, oesophagus,
tongue and skin. These pathologies are accompanied
by activation of a persistent DDR at telomeres,
which induces activation of the p53/p21 and p16 path-
ways resulting in an in vivo cell cycle arrest. The latter
produces dramatic alterations in the properties of the
epithelial stem cells. Thus, morphological develop-
ment of the hair follicles and the sebaceous glands is
completely impaired [34].
(c) Effect of p53 suppression in
TRF1-deﬁcient mice
Suppression of p53 in TRF1
D/DK5-Cre mice rescues
perinatal survival (p53
2/2/TRF1
D/DK5-Cre mice
reach four months of age) and the functionality of epi-
dermal stem cells, as these mice grow hair normally
and do not exhibit skin hyperpigmentation [34].
Longer lived p53
2/2/TRF1
D/DK5-Cre mice, how-
ever, develop epithelial abnormalities similar to
those of human diseases linked to mutations in the
components of shelterin and/or telomerase, such as
nail atrophy and oral leukoplakia. Furthermore,
lack of p53 in p53
2/2/TRF1
D/DK5-Cre mice leads
to the development of spontaneous squamous carci-
nomas, showing that TRF1 acts as a tumour
suppressor by preventing telomere-related genomic
instability.
Our results demonstrate that dysfunction of a single
telomeric protein is sufﬁcient to produce severe telo-
meric damage and loss of telomere capping in the
absence of telomere shortening, leading to premature
tissue ageing, acquisition of chromosomal aberrations
and the development of neoplasic lesions.
The trf1
D/D mouse model is of relevance since it
constitutes the ﬁrst mouse model of ageing induced
by telomere dysfunction in the absence of critical telo-
mere shortening. This model shows that telomere
uncapping and increased telomere fragility do impact
on cancer and ageing in the absence of telomere short-
ening. It also suggests a new class of ‘telopathies’
induced by telomere dysfunction in the presence of
normal-length telomeres.
(d) Tpp1
D/D mice
The role of TPP1 in telomere regulation in vivo and in
mouse development and disease has been poorly
characterized to date owing to lack of mouse models
with complete TPP1 suppression.
We have recently generated Tpp1-deﬁcient MEFs as
well as mice with targeted Tpp1 deletion to the strati-
ﬁed epithelia [36]. Both MEFs and mice deleted for
Tpp1 show induction of telomere damage foci and
cell cycle arrest, demonstrating that TPP1 protects
telomeres from eliciting a DDR. Similarly to TRF1
deﬁciency, Tpp1-null mice die perinatally and show
severe skin hyperpigmentation and defective hair
Review. Telomeres, cancer and ageing L. E. Donate & M. A. Blasco 81
Phil. Trans. R. Soc. B (2011)follicle morphogenesis. These phenotypes are rescued
by p53 suppression, indicating that p53 is a main
effector of proliferative defects associated with Tpp1
deletion.
Unexpectedly, Tpp1 deletion results in decreased
Tert binding to telomeres and accelerated telomere
shortening both in MEFs and mice. Tpp1-null cells
failed to elongate their telomeres when reprogrammed
into pluripotent stem cells, a process that is dependent
on telomerase activity [29,30], thus indicating that
TPP1 is essential for telomere elongation in vivo.
These results suggest a telomere-capping model
where TPP1 not only prevents the induction of a
DDR at telomeres by preventing fusions and telomere
breakage but also is required for telomere elongation
by telomerase.
(e) Rap1
D/D mice
Rap1 is a component of the shelterin complex at mam-
malian telomeres, the in vivo role of which in telomere
biology has remained largely unknown to date.
We have recently generated cells and mice deleted
for Rap1 [37]; mice with Rap1 deletion in stratiﬁed
epithelia are viable but had shorter telomeres and
developed skin hyperpigmentation at adulthood. We
showed that Rap1 deﬁciency is dispensable for telo-
mere capping but leads to increased telomere
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Figure 4. Increased longevity of Sp53/Sp16/SArf/TgTert (SUPER-M) mice. (a) Overall survival. Kaplan–Meier represen-
tation of the survival curves of the indicated mouse cohorts. Only mice that reached at least up to 50 weeks of age were
included. The increase in the median lifespan is indicated. n ¼ number of mice per genotype. Statistical signiﬁcance was
assessed using the log-rank test. (b) Cancer-free survival. Kaplan–Meier representation of the survival curves of mice of the
indicated genotype living for more than 50 weeks excluding those mice that presented malignant tumours at the time of
their death (cancer-free survival). The increase in the median lifespan is indicated. n ¼ number of mice included in the analy-
sis. Statistical signiﬁcance was assessed using the log-rank test. (a) pink trace, Sp53 (n ¼ 68); green trace, Sp53/TgTert (p ¼
0.05; n ¼ 56); red trace, Sp53/Sp16/SArf (n ¼ 39); green trace, Sp53/Sp16/SArf/TgTert (p ¼ 0.05; n ¼ 27)(SUPER-M); pink
trace, Sp53 (n ¼ 68); green trace, Sp53/Sp16/SArf/TgTert (p , 0.001; n ¼ 27)(SUPER-M). (b) pink trace, Sp53 (n ¼ 44);
green trace, Sp53/TgTert (p ¼ 0.47; n ¼ 35); pink trace, Sp53/Sp16/SArf (n ¼ 33); green trace, Sp53/Sp16/SArf/TgTert
(p ¼ 0.001; n ¼ 22)(SUPER-M); pink trace, Sp53 (n ¼ 44); green trace, Sp53/Sp16/SArf/TgTert (p ¼ 0.001; n ¼ 22)
(SUPER-M).
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binds to both telomeres and to extratelomeric
sites. The extratelomeric Rap1-binding sites were
enriched at subtelomeric regions, in agreement with
preferential deregulation of subtelomeric genes in
Rap1-deﬁcient cells.
8. TELOMERES AND LONGEVITY
The embryonic stem cells of mice have long telomeres,
which shorten during embryogenesis (ﬁgure 5). Telo-
mere shortening continues throughout the adult life
of the mice to such a extent that it has been proposed
to be a major cause of mouse ageing since telomere
shortening produces defects in the regenerative
capacity of tissues.
Nuclear reprogramming of differentiated cells
derived from both young and old mice results in
the generation of iPS cells. Telomeres rejuvenate in a
telomerase-dependent manner during nuclear
reprogramming into iPS cells.
Telomere function is highly dependent on func-
tional shelterin components. The suppression of
some shelterin proteins (such as TRF1 and TPP1)
results in sudden development of degenerative pathol-
ogies. Thus, telomere uncapping, even in the presence
of normal length telomeres, is capable of inducing
age-related pathologies in young mice.
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